Q3 Earnings Forecast for ZVRA Issued By William Blair

Key Points

• William Blair estimates Zevra Therapeutics will post Q3 2025 earnings of ($0.06) per share, compared to the consensus estimate of ($1.95) for the full year.
• Zevra Therapeutics reported a quarterly earnings surprise, with earnings of ($0.06) per share beating expectations by $0.15, alongside revenues of $20.40 million.
• Institutional investors are significantly increasing their stakes in Zevra Therapeutics, with notable increases from firms like Adage Capital Partners and AIGH Capital Management.

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - William Blair issued their Q3 2025 earnings per share estimates for shares of Zevra Therapeutics in a report issued on Monday, July 28th. William Blair analyst S. Corwin anticipates that the company will earn ($0.06) per share for the quarter. The consensus estimate for Zevra Therapeutics' current full-year earnings is ($1.95) per share. William Blair also issued estimates for Zevra Therapeutics' Q4 2025 earnings at ($0.05) EPS, Q1 2026 earnings at ($0.04) EPS, Q2 2026 earnings at $0.00 EPS, Q3 2026 earnings at $0.08 EPS and Q4 2026 earnings at $0.14 EPS.

A number of other analysts also recently weighed in on ZVRA. Cantor Fitzgerald boosted their target price on Zevra Therapeutics from $25.00 to $29.00 and gave the stock an "overweight" rating in a research report on Thursday, July 10th. HC Wainwright began coverage on shares of Zevra Therapeutics in a report on Wednesday, July 2nd. They issued a "buy" rating and a $26.00 price objective for the company. Wall Street Zen lowered shares of Zevra Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Sunday, July 20th. Finally, Citigroup reiterated an "outperform" rating on shares of Zevra Therapeutics in a research report on Wednesday, May 14th. Nine analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $23.71.

Zevra Therapeutics Price Performance

ZVRA stock traded up $0.13 during mid-day trading on Thursday, hitting $11.24. 213,637 shares of the stock were exchanged, compared to its average volume of 632,958. The business has a fifty day moving average price of $10.11 and a 200 day moving average price of $8.56. Zevra Therapeutics has a 12 month low of $6.19 and a 12 month high of $13.16. The company has a debt-to-equity ratio of 1.46, a current ratio of 3.02 and a quick ratio of 2.93. The stock has a market capitalization of $614.33 million, a price-to-earnings ratio of -5.90 and a beta of 1.87.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.21) by $0.15. The company had revenue of $20.40 million during the quarter, compared to the consensus estimate of $16.96 million. Zevra Therapeutics had a negative net margin of 226.78% and a negative return on equity of 201.05%. During the same period in the previous year, the firm posted ($0.40) EPS.

Institutional Investors Weigh In On Zevra Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Zevra Therapeutics by 6.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,761 shares of the company's stock valued at $238,000 after acquiring an additional 1,812 shares in the last quarter. Invesco Ltd. lifted its stake in shares of Zevra Therapeutics by 19.6% in the fourth quarter. Invesco Ltd. now owns 18,384 shares of the company's stock worth $153,000 after buying an additional 3,007 shares in the last quarter. Carret Asset Management LLC boosted its stake in Zevra Therapeutics by 9.7% during the 2nd quarter. Carret Asset Management LLC now owns 39,640 shares of the company's stock valued at $349,000 after purchasing an additional 3,500 shares during the last quarter. Corebridge Financial Inc. raised its stake in shares of Zevra Therapeutics by 16.9% in the fourth quarter. Corebridge Financial Inc. now owns 26,294 shares of the company's stock worth $219,000 after purchasing an additional 3,801 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in Zevra Therapeutics by 2.6% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 153,331 shares of the company's stock worth $1,148,000 after buying an additional 3,827 shares in the last quarter. Hedge funds and other institutional investors own 35.03% of the company's stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.